不同促排卵方案在多囊卵巢综合征患者IVF-ET中的应用

目的:探讨三种促排卵方案在多囊卵巢综合征(PCOS)患者体外受精-胚胎移植(IVF-ET)周期的临床应用比较。方法:PCOS患者根据用药情况分为传统长效促性腺激素释放激素激动剂(GnRHa)长方案A组20周期、短效GnRH-a长方案B组26周期和来曲唑微刺激方案C组22周期,比较三组患者的促排卵参数和临床结局。结果:1A组Gn使用天数及用量、HCG注射日血清E2高于B、C组,临床妊娠率低于B、C组(P<0.05);A组HCG注射日血清LH、正常受精率、卵裂率、优质胚胎率低于C组,获卵数、OHSS发生率高于C组(P<0.05),但在与B组组间比较,差异均无统计学意义(P>0.05);A组HCG日血清P、子宫内膜厚度、周期取消率和冷冻胚胎数与B、C组组间比较,差异无统计学意义(P>0.05)。2B组Gn用量、HCG日血清E2、获卵数、OHSS发生率高于C组、HCG日血清LH、P、正常受精率、临床妊娠率低于C组(P<0.05);B组Gn天数、HCG日子宫内膜厚度、卵裂率、优质胚胎率、周期取消率和冷冻胚胎数与C组组间比较,差异无统计学意义(P>0.05)。结论:来曲唑微刺激方案临床效果优于长效与短效GnRHa长方案,同时降低Gn使用总量,减轻患者单周期治疗费用,是PCOS患者较理想的促排卵方案。     

垂体降调节后延迟卵巢启动时间对体外受精-胚胎移植结局的影响

目的 探讨体外受精-胚胎移植(IVF-ET)中应用半量长效促性腺激素释放激素激动剂(GnRHa)降调节后,延迟超促排卵(COH)启动时间对实验室和临床结局等的影响.方法 将IVF中207个周期分为对照、常规和延迟组:对照组98周期于黄体中期予短效GnRHa 0.1 mg/d,月经第3 d减半,常规组63周期和延迟组46周期于黄体中期予长效GnRHa 1.87 mg;对照组和常规组于月经第3 d加用促性腺激素(Gn),延迟组于第7 d加用Gn,观察在IVF-ET中临床和实验室的结局是否有差异.结果 常规组的取消周期数最多(P＜0.01).COH启动日,延迟组和对照组E2、LH水平高于常规组(P均＜0.01).HCG注射日,对照组的E2水平最高;延迟组和对照组中LH水平高于常规组(P均＜0.01),刺激天数和Gn用量少于常规组(P均＜0.005),获卵数、受精率、可移植胚胎数、临床妊娠率、胚胎种植率和MⅡ期卵子高于常规组(P均＜0.05);延迟组中重度卵巢过度刺激综合征(OHSS)的发生少于常规组.结论 延迟COH启动时间可减少卵巢刺激时间、Gn用量,增加获卵数、成熟卵子数、可移植胚胎数和胚胎种植率,提高IVF的妊娠率.     

穿刺GnRH-a诱发的卵巢囊肿对体外受精-胚胎移植结局的影响

目的观察穿刺GnRH-a诱发的卵巢囊肿对体外受精-胚胎移植结局的影响。方法选择生殖中心行黄体期长方案IVF/ICSI助孕的患者70例,在黄体期注射长效GnRH-a后出现卵巢囊肿,其中A组(35周期)行囊肿穿刺,B组(35周期)未行囊肿穿刺,比较两组之间临床过程(Gn的用量、获卵数)、实验室结果(受精率、卵裂率、可移植胚胎率)及妊娠结局(妊娠率、流产率)。结果 A组妊娠14例,妊娠率40.0%;B组妊娠20例,妊娠率57.1%。两组在Gn用量、Gn时间、获卵数、受精数、卵裂率、移植胚胎个数、可移植胚胎率、妊娠率及流产率等方面差异无统计学意义(P>0.05)。结论长方案IVF/ICSI中应用GnRH-a后出现卵巢囊肿进行囊肿穿刺不改善体外受精-胚胎移植的结局。     

改良超长降调节方案在体外受精-胚胎移植中的应用

目的探讨改良超长降调节方案结合人绝经期促性腺激素(HMG)在体外受精-胚胎移植(IVF-ET)中的应用。方法对一次降调不全患者采用改良超长方案降调节,行IVF-ET的49例患者(50周期)作为试验组(A组),随机选择同期常规长方案降调节行IVF-ET的46例患者(51周期)作为对照组(B组)。比较两组间年龄、不孕时间、IVF周期数、总AFC数、启动Gn剂量、Gn天数、Gn总量、获卵数、MII率、受精率、卵裂率、优质胚胎率、流产率、总药费支出。结果两组间患者年龄、不孕时间、IVF周期数、总AFC数、Gn天数、Gn总量、获卵数、MII率、受精率、卵裂率、优质胚胎率、流产率差异无统计学意义(P>0.05);启动Gn剂量A组大于B组,差异有统计学意义(P<0.05)。总药费支出A组小于B组,差异有统计学意义(P<0.05);妊娠率A组(56.00%)大于B组(45.10%),但是差异无统计学意义(P>0.05)。结论改良超长降调节结合HMG促排卵对一次降调不全的IVF-ET患者可以得到较理想的妊娠结局,并明显降低费用。     

OHSS高危患者两种移植方案的临床结局分析

目的比较研究控制性超促排卵(COH)周期患者移植日前有卵巢过度刺激综合征(OHSS)高危因素时行全胚胎冷冻以及行新鲜周期移植的两种方案的临床结局。方法回顾性分析接受COH治疗且取卵前出现OHSS高危因素的患者267例,随机分为A、B两组。A组:全胚胎冷冻并行首次解冻胚胎移植的122例;B组:行新鲜周期胚胎移植的145例。对两组患者的年龄、不孕年限、不孕因素、身体质量指数(BMI)、COH情况[促性腺激素(Gn)启动剂量、超排天数、Gn总量、注射人绒毛膜促性腺激素(HCG)日内膜、HCG日雌二醇(E2)水平、HCG日卵巢大小]、获卵数、优质胚胎数、重度OHSS发生率、新鲜周期及复苏周期的生化妊娠率、临床妊娠率进行比较分析。结果两组患者年龄、不孕年限、不孕因素、BMI、COH情况、获卵数、优质胚胎数差异无统计学意义。A组患者重度OHSS的发生率(2.46%)显著低于B组(8.28%),差异有统计学意义(P<0.05)。两组的生化妊娠率(50.0%vs 47.6%)、临床妊娠率(36.9%vs33.8%),差异无统计学意义。结论与新鲜周期移植比较,OHSS高危患者行全胚胎冷冻后复苏周期移植不影响患者的临床结局,但其明显降低了重度OHSS的发生率,使安全性提高并降低了医疗费用。     

重组人促黄体生成素在IVF促排卵中的研究

目的:探讨在体外受精(in vitro fertilization,IVF)降调抑制过深的患者中添加重组人促黄体生成素(rhLH)对卵巢功能和妊娠结局的影响。方法:选取郑州大学第一附属医院2012年1月至2013年1月行IVF长方案降调节后LH≤0.5 IU/L的患者375例,随机分为两组,A组(181例):启动促性腺激素(Gn)单用重组人促卵泡激素(r-FSH),第6天开始添加r-hLH 75 U/d。B组(194例):启动Gn,应用r-FSH同时添加rhLH 75 U/d,比较两组患者的Gn用量及天数、人绒毛膜促性腺激素(HCG)注射日E2、LH值、获卵数、2PN数、优质胚胎数、着床率、临床妊娠率。结果:Gn用量、HCG注射日E2值、获卵数,两组比较差异无统计学差异(P>0.05),但Gn天数、HCG注射日LH值、2PN数、优质胚胎率、着床率、临床妊娠率方面,B组优于A组,两组比较差异有统计学意义(P<0.05)。结论:及早添加r-hLH可以获得较高的双原核胚胎数、着床率及临床妊娠率。     

促性腺激素释放激素激动剂联合人绒毛膜促性腺激素诱导卵泡成熟在拮抗剂方案中的疗效比较

目的 探讨促性腺激素释放激素(GnRH)拮抗剂促排卵方案中联合使用GnRH激动剂(GnRHa)和人绒毛膜促性腺激素(HCG)诱导卵泡成熟治疗的安全性和有效性.方法 采用回顾性病例对照研究设计,回顾性分析因多囊卵巢综合征和输卵管因素复合病因行GnRH拮抗剂方案并联合GnRHa和HCG诱导卵泡成熟治疗的不孕症患者(A组),共41个体外受精(IVF)周期.同期根据年龄、体质指数(BMI)和不孕症病因配对41个IVF周期,行GnRH拮抗剂方案并使用GnRHa诱导卵泡成熟(B组)作对照.结果 两组基础FSH水平、获卵数和优质胚胎数的差异无统计学意义(P＞0.05).A组临床妊娠率和活产率均高于B组,但差异无统计学意义(P＞0.05).A组新鲜周期取消率高于B组但差异无统计学意义(P＞0.05).两组移植后均无卵巢过度刺激综合征(OHSS)发生.结论 对于非OHSS超高危患者,GnRH拮抗剂方案中联合GnRHa和HCG诱导卵泡成熟较单用GnRHa诱导卵泡成熟可以部分提高临床妊娠率和活产率,但不会显著增加OHSS发生率.     

全胚冷冻中胚胎移植管选择对妊娠结局的影响

目的 探索两种胚胎移植管对全胚冷冻后首次胚胎移植的患者临床妊娠结局的影响.方法 回顾性分析行全胚冷冻后首次冻融移植周期,依据使用的移植管分成两组,A组采用COOK-K-JETS-7019-SIVF移植管(200个周期);B组采用Edwarda-Wallace移植管(242个周期),观察并比较两组患者的一般情况及妊娠结局.结果 两组在对应取卵周期的年龄、BMI、血清bE2、bFSH、bLH、Gn使用量和使用时间、HCG日LH、HCG日E2、获卵数、总受精数、优质胚胎数、移植日内膜厚度及移植胚胎数目之间的差异均无统计学意义(P＞0.05);A组的胚胎种植率、临床妊娠率均高于B组,差异有统计学意义(P＜0.01).结论 质地柔软、顺应性较好的胚胎移植管可以获得更好的妊娠结局.     

选择性单胚胎移植临床结局和可行性分析

目的 探讨行选择性单胚胎移植(eSET)的临床结局及可行性.方法 回顾性分析2014年8月至2015年10月在该院生殖科进行体外受精-胚胎移植(IVF-ET)治疗的患者资料,选择行选择性移植1枚优质胚胎106个周期为eSET组,其中获卵数大于15个为高反应组(高度OHSS风险,46个周期),获卵数5～15个为正常反应组(60个周期).移植2枚胚胎(至少1枚为优质胚胎)的106个周期为双胚胎移植组(DET)组.比较组间一般情况、促排情况、胚胎发育情况及临床妊娠率、种植率、多胎率和早期流产率.结果 eSET组Gn量和双胎妊娠率低于DET组,注射人绒毛膜促性腺激素(HCG)日雌激素(E2)水平、获卵数、优质胚胎数和种植率均高于DET组,比较差异有统计学意义(P<0.05).高反应组注射HCG日E2水平高于正常反应组,比较差异有统计学意义(P<0.05).结论 eSET与DET有相似的妊娠率,但能明显降低双胎妊娠率,对于特定人群应该坚持行eSET.     

不同GnRH-a降调节方案用于子宫内膜异位症合并不育者的体外受精-胚胎移植研究

目的比较子宫内膜异位症(EMS)合并不育妇女采用不同促性腺素释放激素激动剂(GnRH-a)降调节方案进行体外受精-胚胎移植(IVF-ET)助孕治疗的结局。方法将2008年1月至2010年12月以超长方案行IVF-ET的各型EMS合并不育患者74例(A组)与同期用长方案患者177例(B组)进行回顾性分析,比较两组患者的助孕结局。结果 A组EMS病情比B组重,促性腺激素(Gn)起始剂量及总量更大,卵泡数、获卵数及获成熟卵数较少,差异有统计学意义(P<0.05)。两组受精率、卵裂率、周期取消率、可移植胚胎数、优质胚胎数及ET胚胎数、流产率、异位妊娠率比较,差异均无统计学意义(P>0.05)。A组可移植胚胎率、优质胚胎率明显高于B组(P<0.05)。A组临床妊娠率、种植率均比B组高,但差异均无统计学意义(P>0.05)。结论超长方案用于EMS患者的IVF-ET助孕有助于改善胚胎质量,且有提高妊娠率及种植率的趋势。     

影响再次IVF/ICSI-ET助孕结局的相关因素分析

目的分析影响再次体外受精-胚胎移植(IVF-ET)鲜胚周期助孕结局的因素,以进一步改善其结局。方法回顾性分析45例(90个周期)首次IVF/ICSI-ET助孕失败并接受再次IVF-ET鲜胚移植周期的情况,对可能影响妊娠结局的相关因素进行单因素分析和Logistic多因素回归分析。结果再次IVF/ICSI-ET获得临床妊娠23例、未孕22例,单因素分析结果显示妊娠组妊娠周期移植后黄体支持加用补佳乐剂量(4.73±2.49)mg/d与(3.5±2.63)mg/d、联用HCG剂量(1 318.18±945.48)IU/次与(636.36±953.46)IU/次显著高于首次未孕周期,差异均有统计学意义(t=2.113,P=0.047;t=2.83,P=0.01)。再次IVF/ICSI-ET获得临床妊娠组自身前后周期Logistic回归分析显示,移植后联用HCG(OR=1.001)、是否进行内膜修整(OR=0.143)与再次IVF/ICSI-ET临床妊娠结局相关(P<0.05)。再次周期未孕组与妊娠组各单因素比较,差异无统计学意义(P>0.05)。结论内膜修整、适当的黄体支持是影响再次IVF/ICSI-ET助孕是否妊娠的重要因素,重视这些环节是提高和改善再次IVF助孕结局的重要方面。     

Assisted reproductive technology treatment costs of a live birth: an age-stratified cost-outcome study of treatment in Australia

OBJECTIVES: To calculate the cost of assisted reproductive technology (ART) treatment cycles and resultant live-birth events. DESIGN: Cost-outcome study based on a decision analysis model of significant clinical and economic outcomes of ART. SETTING AND PARTICIPANTS: All non-donor ART treatments initiated in Australia in 2002. Treatment cycles, maternal age and birth outcome data were obtained from the Australian and New Zealand Assisted Reproduction Database. Direct health care costs were obtained from fertility centres, and included government, private insurer and patient costs. MAIN OUTCOME MEASURES: Average health care cost of non-donor, fresh and frozen embryo ART treatment cycles. Average and age-specific costs per live-birth event following ART treatment. RESULTS: Average health care cost per non-donor ART live-birth event was 32,903 US dollars (range, 24,809 US dollars for women < 30 years to 97,884 US dollars for women > or = 40 years). The cost per live birth for women aged > or = 42 years was 182,794 US dollars. The average treatment cost of a fresh cycle was 6,940 US dollars, compared with 1,937 US dollars for a frozen embryo transfer cycle. CONCLUSIONS: Debate regarding funding for ART services has been hindered by a lack of economic studies of ART treatments and outcomes in Australia. This is the most comprehensive costing study of ART services to date in terms of resources consumed during ART treatment. It confirms that ART treatment is less cost-effective in older women. Alongside economic considerations of ART, community values, ethical judgements and clinical factors should influence policy decision-making.     

辅助生殖技术治疗周期中单侧卵巢对超促排卵及妊娠的影响

目的了解辅助生殖技术(ART)治疗周期中单侧卵巢对超促排卵效果及临床结果的影响.方法对2001年1月～2003年12月3 a内在湘雅医院生殖医学中心接受ART治疗的30个单侧卵巢病例进行分析,了解ART周期治疗前单侧卵巢切除的原因,比较单侧与双侧卵巢患者超促排卵后获卵数及注射HCG日E2水平、植入率及临床妊娠率的差异.结果ART治疗前手术切除一侧卵巢的原因以卵巢病变及宫外孕为主,且单侧卵巢超促排卵后促性腺激素(Gn)用量、用药时间、受精率、卵裂率及妊娠率与双侧卵巢比较差异无显著性(P＞0.05),而注射HCG日E2水平及获卵数较双侧卵巢为低(P＜0.01).结论ART周期中单侧卵巢行IVF-ET时虽临床妊娠率与双卵巢无差异,但注射HCG日E2水平及获卵数低于双侧卵巢,因此对良性卵巢病变生育前应尽量采取保守性手术.     

The oral contraceptive pill effectively permits cycle batching for an intermittent in vitro fertilization programme in Trinidad and Tobago

Assisted reproductive technology (ART) in small island states like Trinidad and Tobago is usually provided in batches so as to minimize the cost of providing the service. As a result, patients 'cycles have to be synchronized in order to coincide with the arrival of a visiting embryologist. This is a retrospective study which evaluates the experience of pre-treatment with an oral contraceptive pill (OCP) as a means of batching cycles for an intermittent ART programme. Seventy-four in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles in which OCP usage was employed (Group A), were compared with 121 cycles which did not require pharmaceutical manipulation (Group B). In both groups more than 50% of women were older than 36-years. Two cycles were cancelled in Group A and seven in Group B, because of poor ovarian response. Although the pregnancy rate per treatment cycle was higher in Group A than in Group B (26.3% vs 17.3%), this difference was not significant. More spontaneous miscarriages occurred in the non-OCP women and ovarian cyst formation was more common in these women. The authors experience indicates that the OCP is a simple, cheap and efficient means of batching patients for an intermittent ART programme and can be utilized in other small ART centres.     

Does HPV infection do harm to IVF outcomes and subsequent pregnancy outcomes?

研究背景：因不孕症行IVF助孕患者成功率及妊娠结局是否受HPV感染影响一直存在争议,本文通过数据观察希望能得到更近一步的结果。 方法：回顾性分析3880例新鲜周期IVF助孕病例,TCT异常并行新鲜周期胚胎移植患者分为2组,HPV阳性组（n=56）和HPV阴性组（n=56）。两组数据比较应用t检验和卡方检验方法。对于HPV对临床妊娠组与非临床妊娠组的影响应用单因素及多因素分析描述。 结果： 3880病例中157例合并TCT异常（4%）。149例患者行HPV HCII检测,其中112例患者（81.2%）接受新鲜周期胚胎移植术。HPV阴性和阳性组分别56例,比较两组患者年龄、BMI均相似,不孕因素分类亦相似。IVF过程中促性腺激素用量、获卵数、临床妊娠率和流产率以及新生儿出生体重等均无明显差异。多因素分析提示无论HPV阳性与否或是HPV HC II滴度高低均对IVF后临床妊娠率无显著影响。 结论： HPV阳性似乎不影响人工助孕后成功率。作者不推荐在IVF周期前“过度治疗”HPV感染,因为时间的延误使患者年龄增大,可能会进一步降低卵巢功能,而卵巢功能降低才是影响IVF术后成功率的主要原因。     

辅助生殖技术治疗中子宫畸形对妊娠结局的影响

目的 探讨不孕女性行辅助生殖技术(ART)助孕治疗过程中子宫畸形对妊娠结局的影响。方法 选取2015年5月至2021年5月期间于皖南医学院第一附属医院弋矶山医院生殖医学中心接受ART助孕的不孕女性中子宫畸形患者作为试验组纳入,共34周期;机械抽样选取同时期接受ART助孕符合纳入标准的子宫正常的患者,作为对照组纳入,共73周期。收集两组患者的一般资料、激素水平、试验室指标、妊娠结局进行回顾性分析;依据子宫畸形的不同类型将试验组分为5组,分别对5组患者妊娠结局进行统计。结果 子宫正常组与子宫畸形组的临床妊娠率、单胎率、双胎率、活产率、早期流产率、中晚期流产率比较,差异无统计学意义(P>0.05)。子宫畸形5个亚组,临床妊娠率、单胎率、双胎率、活产率、早期流产率、中晚期流产率比较,差异均无统计学意义(P>0.05)。结论 ART治疗中子宫畸形不是妊娠结局的主要影响因素。     

A Bahraini Registry of Assisted Reproductive Technology for Period of 2000-2006: Hoping to Stave off Reporting Stalemate

Objective To report the first Bahrain national registry for ART treatments initiated from January 1, 2000 to December 31, 2005. Methods The ＂World Report on ART＂ forms, prepared by the International Committee for Monitoring Assisted Reproductive Technology （ICMART）, were filled from database records of all procedures and their respective outcome carried out at Banoon ART Centre, the Military Hospital, Bahrain during the period of 2000-2006. Results A total of 1490 completed cycles were performed. ICSI constituted 42.68% （636）, IVF constituted 35.50% （529）, while frozen-thawed embryo replacement cycles represented only 21.18% （325） of all ART cycles. The clinical pregnancy rates per transfer for IVF and ICSI cycles were 26.65% and 21.70%, respectively. The distribution of singleton, twin and triplet deliveries for IVF,, ICSI and FET combined were 80. 0%, 16.3% and 3.7%, respectively. The average delivery rate per clinical pregnancy for fresh and frozen cycles was 57.3%. As a result of ART services, 266 neonates were born. Complications of ART were solely due to ovarian hyperstimulation syndrome （OHSS） which constituted 2.26% of all aspirated cycles. Conclusion Multiple pregnancy rate was high due to transferring 〉3 embryos. Pregnancy loss and OHSS were relatively high thus preventative measures were recommended. This report paves the way for the other IVF centers in Bahrain to provide their own data for the national ART registry.     

Antiretroviral Therapy in the Malawi Police Force: Access to Therapy and Treatment Outcomes

A national survey was carried out in all the 103 public sector and 38 private sector facilities in Malawi providing antiretroviral therapy (ART) to determine uptake of ART and subsequent treatment outcomes in police force personnel. All patients registered for ART and their subsequent treatment outcomes were censored on December 31st 2006. There were 85168 patients started on ART in both public and private sectors, of whom 463 (0.6%) were police force personnel. Of police force personnel starting ART, 17% were in WHO clinical stage 1 or 2 with a CD4-lymphocyte count of ≤250 cells/µL and 83% were in stage 3 or 4. Treatment outcomes of police force personnel by the end of December 2006 were 302 (65%) alive and on ART at their registration facility, 59 (13%) dead, 30 (7%) lost to follow-up, 1 stopped treatment and 71 (15%) transferred to another facility. Their probability of being alive on ART at 6-, 12- and 18-months was 83.2%, 78.6% and 76.7% respectively. There has been a good access of police force personnel to ART since national scale up commenced with good treatment outcomes, and this should serve as an example for other police forces in the region.     

卵子冷冻技术的临床应用

目的 探讨卵母细胞冷冻技术在临床应用.方法 将258例接受体外受精-胚胎移植(IVF-ET)和单精子卵浆内注射(ICSI)治疗,取卵数≥20枚的258个周期,分为部分卵母细胞冷冻组(简称冻卵组)84个周期和胚胎冷冻组(简称冻胚组)174个周期,比较两组新鲜周期受精率和临床妊娠率.总结了23个卵母细胞冷冻复苏周期及19个移植周期(其中4个周期为捐赠周期)的复苏率,受精率,卵裂率,胚胎种植率,临床妊娠率,比较冻胚组冻胚复苏移植的临床结局.结果 冻卵组和冻胚组新鲜周期的受精率和临床妊娠率差异无统计学意义(P>0.05);19个卵母细胞冷冻复苏的移植周期与56个冷冻胚胎复苏的移植周期的胚胎种植率和临床妊娠率差异亦无统计学意义(P>0.05);卵母细胞冷冻复苏的移植周期妊娠率为47.4%(9/19),其中冻卵捐赠4个移植周期,2例临床妊娠(1例已分娩).结论 对于接受IVF/ICSI治疗的不孕妇女,由卵巢刺激产生的较多卵母细胞,无论是否选择冷冻部分卵母细胞,对其新鲜周期的受精率和妊娠率没有影响;冻卵移植周期与冻胚移植周期的妊娠率差异也无统计学意义;但是卵母细胞冷冻在生育力保存和分享捐赠方面较冻胚具有显著的优势.     

Clinical Observations of Sequential Therapy with Chinese Medicine and Hysteroscopic Mechanical Stimulation of the Endometrium in Infertile Patients with Repeated Implantation Failure Undergoing Frozen-Thawed Embryo Transfer

Objectives: To investigate the clinical effect of sequential therapeutic intervention Yupei Qisun [compensating for weakness by invigorating Kidney (Shen) and Spleen (Pi) in advance] in Chinese medicine (CM) and hysteroscopic endometrial mechanical stimulation on the treatment of infertile patients with repeated implantation failure (RIF); and to study the differences in patients'' endometrial thickness and type on the day of embryo transfer, serum hormone levels on embryo transfer day and clinical pregnancy outcomes. Methods: In the clinical study, 168 frozen-thawed embryo transfer (FET) cycles for couples with RIF conforming to the research protocol were randomly divided into three groups: a CM group with 56 cycles (CM combined with FET), a hysteroscopy group with 55 cycles (hysteroscopic endometrial mechanical stimulation), and a control group with 57 cycles (conventional FET). Differences in endometrial thickness on the embryo transfer day, levels of serum estradiol (E2) and progesterone (P) on the embryo transfer day, the E2/P ratio on the embryo transfer day, biochemical and clinical pregnancy rates, implantation rate, abnormal pregnancy rate and other indices were compared among the three groups. Results: Endometrial thickness, E2 and P levels, and the E2/P ratio on embryo transfer day and other factors had no significant differences among groups. The biochemical pregnancy, clinical pregnancy, and implantation rates of the CM and hysteroscopy groups were significantly higher than the control group (P<0.05), and there were no significant differences between these two groups. The abnormal pregnancy rate had no significant difference among the three groups. Conclusions: Sequential therapy of Yupei Qisun could significantly improve the clinical outcomes of RIF-FET cycles, being equivalent to hysteroscopic endometrial mechanical stimulation, and provided a reliable method to treat such infertile couples.